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Abstract
Background: The aim of this study was to assess antiplatelet effect of prasugrel in acute 
coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) on clo-
pidogrel, undergoing percutaneous coronary intervention (PCI).
Methods: A prospective, platelet reactivity-guided, parallel-group, open-label study including  
71 patients pretreated with clopidogrel 600 mg and assigned either to prasugrel (30 mg loading dose, 
10 mg maintenance dose; n = 46) or clopidogrel (150 mg maintenance dose for 6 days and thereafter 
75 mg maintenance dose; n = 25) regimen, based on vasodilator-stimulated phosphoprotein (VASP)-
-assessed platelet reactivity index (PRI; > 50% vs. ≤ 50%) measured next morning post-PCI.
Results: Median PRI value after switch to prasugrel sharply declined at 24 h (70.0 [61.3– 
–75.6] vs. 11.9 [6.8–25.7]%; p < 0.000001) and slightly but significantly rose between 24 h and 
30 days (27.9 [15.5–46.8]%; p < 0.0006). In contrast, median PRI values in the clopidogrel 
group were similar at baseline and at 24 h (25.1 [13.7–40.2] vs. 22.0 [18.4–36.8]%; p = NS) 
and then modestly rose at 30 days (30.3 [20.4–45.7]%; p < 0.03). The prevalence of HTPR 
decreased in the prasugrel group between baseline and 24 h measurements (100.0 vs. 4.3%;  
p < 0.0001). Rates of patients with HTPR at 24 h and 30 days were similar in both groups, so 
were the tendencies in patterns of platelet inhibition evaluated with multiple electrode aggrego-
metry as compared with the VASP assay.
Conclusions: Our study indicates that prasugrel overcomes HTPR on clopidogrel in the acute 
phase of interventionally treated ACS and maintains its antiplatelet potency in 30-day follow-
-up. Potential clinical benefits of personalized antiplatelet prasugrel-based therapy warrant 
further investigation in clinical ACS trials. (Cardiol J 2014; 21, 5: 547–556)
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Introduction
The modest potency and large interindividual 
variability of clopidogrel may result in its insufficient 
antiplatelet effect in some patient subsets [1, 2]. 
Subsequently, subjects with high on-treatment pla-
telet reactivity (HTPR) on clopidogrel are exposed 
to increased risk of cardiovascular (CV) events in 
the setting of percutaneous coronary intervention 
(PCI) [3].
Prasugrel is associated with a faster onset of 
action and enhanced inhibition of platelet aggrega-
tion than clopidogrel and was shown to reduce CV 
events more effectively than clopidogrel in patients 
with acute coronary syndrome (ACS) undergoing 
PCI [4, 5].
Assuming that a 30 mg loading dose of prasu-
grel followed by a 10 mg maintenance dose would 
produce an efficient platelet P2Y12 receptor blocka-
de in ACS patients treated with PCI and resistant 
to the initial 600 mg loading dose of clopidogrel, we 
aimed in the present study to test the antiplatelet 
effect of prasugrel in interventionally treated ACS 
patients with HTPR.
Methods
Study population and design
The study was designed as a prospective, sin-
gle-center, non-randomized, investigator-initiated, 
platelet reactivity-guided, parallel-group, open-
label trial. Consecutive patients admitted to The 
Department of Cardiology and Internal Medicine 
between 15 November 2010 and 31 December 2011 
were screened with respect to their eligibility for 
the study enrolment. Inclusion criteria were as 
follows: age between 18 and 74 years, ACS suc-
cessfully treated with PCI with stent implantation, 
pre-treatment with loading doses of clopidogrel 
(600 mg) and aspirin (300 mg), and platelet function 
assessment available between 12 and 24 h after 
PCI. Patients were excluded from the study in the 
presence of at least of one of the following criteria: 
age equal or above 75 years, prior transient ische-
mic attack or stroke, body weight less than 60 kg, 
contraindication for aspirin and/or thienopyridines, 
the need for anticoagulation in the following month 
or prior chronic anticoagulation, chronic treatment 
with a thienopyridine or non-thienopyridine plate-
let P2Y12 receptor blocker, necessity for coronary 
artery bypass grafting in the following month, 
current bleeding disorder, active bleeding event, 
active peptic ulcer disease, history of gastrointes-
tinal bleeding within the prior month, severe liver 
failure (Child Pugh class C), hemoglobin level at 
presentation below 90 g/L, platelet count below 
100 000/mL and ongoing pregnancy.
Based on the initial platelet function as-
sessment performed on the next morning following 
PCI, patients were assigned to one of 2 particular 
thienopyridine regimens (Fig. 1). Blood samples 
were collected at 10.00 a.m. as we previously de-
monstrated that platelet inhibition by clopidogrel 
is weaker in the midmorning hours [6]. Subjects 
with HTPR on clopidogrel defined as the platelet 
reactivity index (PRI) above 50% were immediately 
loaded with 30 mg of prasugrel with a subsequent 
maintenance dose of 10 mg q.d. until the end of the 
study. Patients with adequate platelet inhibition 
(PRI £ 50%) received a 150 mg maintenance dose 
of clopidogrel q.d. for 6 days and thereafter a 75 mg 
maintenance dose q.d.
All participants provided informed written 
consents for participation in the study. The study 
protocol was approved by the Local Ethics Commit-
tee in accordance with the Declaration of Helsinki.
Coronary arteriography and PCI
Interventional procedures were performed 
according to current guidelines [7]. Abciximab or 
eptifibatide were administered at the discretion of 
the invasive cardiologist in doses recommended 
by the drug manufacturers.
Assessment of platelet reactivity
We applied 2 independent methods to assess 
platelet reactivity.
A standardized flow cytometric assay (VASP; 
BioCytex, Marseille, France) was used to deter-
mine the inhibition by adenosine diphosphate 
(ADP) of phosphorylation of vasodilator-stimulated 
phosphoprotein (VASP), which is mediated by the 
P2Y12 receptor through the inhibition of adenylyl 
cyclase. The VASP assay is regarded as the most 
specific tool assessing the effect of thienopyridine 
or non-thienopyridine blockers on the platelet 
P2Y12 receptor. Platelet reactivity was expressed 
as PRI calculated as a percentage according to the 
formula: [(GMFI(PGE1) – GMFI(PGE1 + ADP))/GMFI(PGE1)] 
× 100. The ratio is expressed as mean percenta-
ge platelet reactivity, inversely correlated with 
clopidogrel or prasugrel treatment efficiency. The 
normal value of PRI without treatment with ADP 
antagonists is 69–100% [8].
Whole blood aggregation was determined 
using multiple electrode aggregometry (MEA) 
on a new generation impedance aggregometer 
(Multiplate Analyzer, Verum Diagnostica GmbH, 
Munich, Germany) according to the manufacturer’s 
instructions. The instrument detects the impe-
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dance change related to platelet aggregation and 
transforms it into arbitrary aggregation units (AU) 
that are plotted against time. The area under the 
aggregation curve (AUC) is an estimator of plate-
let aggregation that was evaluated in our study. 
Aggregation, quantified as the AUC, is displayed in 
arbitrary units (10 AU × min = 1 U) [9]. To assess 
the platelet response to clopidogrel or prasugrel, 
we applied ADP-induced aggregation. A good re-
producibility of MEA, with the variability of results 
< 6%, was reported by Tóth et al. [9].
Study definitions and endpoints
The primary HTPR definitions (PRI > 50% 
and AUC > 46.8 U for VASP and MEA, respecti-
vely) were based on the consensus document of the 
Working Group on On-Treatment Platelet Reactivi-
ty and prior studies indicating a strong link between 
increased platelet reactivity and the occurrence of 
stent thrombosis and recurrent ischemic events 
[1, 10–15]. To strengthen our findings we also 
applied in the calculations other clinically validated 
HTPR definitions (PRI > 60% [16, 17] and AUC 
> 54 U [18] for VASP and MEA, respectively).
Values of PRI measured 24 h and 30 days 
after assignment to the particular thienopyridine 
regimen constituted the primary study end points, 
while values of ADP-induced platelet aggregation 
determined by MEA, rates of HTPR according the 
VASP assay and MEA, all at 24 h and at 30 days 
Figure 1. Flow diagram of the study; ACS — acute coronary syndrome; ADP — adenosine diphosphate; HTPR — high 
on-clopidogrel platelet reactivity; MEA — multiple electrode aggregometry; PRI — platelet reactivity index; VASP — 
vasodilator-stimulated phosphoprotein.
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were selected as the secondary study end points. 
MEA measurements at baseline and after 24 h 
were restricted only to the patients not receiving 
glycoprotein (GP) IIb/IIIa inhibitors. Blood samples 
for platelet function assessment at 24 h and at 
1 month were collected at 10.00 a.m. Additionally, 
we prespecified to report all cases of death, new on-
set myocardial infarction, definite stent thrombosis, 
new onset chronic heart failure and bleeding events 
of any severity occurring in the study participants 
during the study period.
Statistical analysis and sample  
size calculation
Based on a study conducted by Bonello et 
al. [14] we assumed the mean value of PRI in 
HTPR patients pretreated with clopidogrel 600 mg 
of 68.5 ± 10.3%. Similarly, we expected that 
additional administration of 30 mg of prasugrel in 
HTPR patients who had received a 600 mg loading 
dose of clopidogrel would decrease PRI to a value 
comparable with that observed in clopidogrel-naive 
patients after treatment with a 60 mg loading dose 
of prasugrel (34.3 ± 23.1%) [19]. Additionally, we 
anticipated in our prasugrel-treated patients to 
obtain PRI values at 30 days comparable to these 
observed in the TRITON-TIMI 38 platelet substu-
dy at this time point (33.6 ± 2.9%) [20]. Bearing 
in mind these results and assuming a 2-sided alpha 
value of 0.05, we calculated, using the t-test for 
dependent variables, that enrolment of 46 HTPR 
patients would provide a 99.9% power to demon-
strate significant reductions in PRI associated with 
the implementation of prasugrel-based antiplatelet 
regimen between its baseline value and both values 
at 24 h and 30 days.
The Shapiro-Wilk test was used to demonstra-
te whether the investigated continuous variables 
were normally distributed. Therefore, continuous 
variables with and without normal distribution 
were presented as mean values ± standard devia-
tions or as medians and their interquartile ranges, 
respectively. Depending on the presence or absen-
ce of normal distribution, intergroup comparisons 
were performed with the Student’s t-test for in-
dependent samples or the Mann-Whitney unpaired 
rank sum test, whereas the Student’s t-test for 
paired samples or the Wilcoxon matched-paired 
rank sum test were applied for comparisons within 
the groups. Independent categorical variables were 
compared using the c2 test with the Yates’ correc-
tion if required. Dependent qualitative data were 
assessed with the McNemar’s test. Correlations 
were tested with the Spearman rank correlation 
test. A value of two sided p < 0.05 was regarded 
as statistically significant; 0.05 £ p < 0.1 was 
considered a trend towards statistical significance, 
while p £ 0.1 was marked as non-significant (NS). 
The statistical analysis and sample size calcu-
lation were carried out using the Statistica 10.0 
package (StatSoft, Tulsa, OK, USA) and MedCalc 
12.0 (MedCalc Software, Mariakerke, Belgium) 
statistical software.
Results
Study population
A total of 151 individuals were screened 
with respect to their eligibility for the study and 
74 patients were eventually enrolled in the study 
(Fig. 1). All study participants received allocated 
antiplatelet regimen. However, 3 patients were 
excluded from the primary analysis. Finally, 
71 patients (46 and 25 patients in the prasugrel and 
clopidogrel groups, respectively) were included in 
the primary analysis.
Baseline demographic and clinical characteri-
stics of the study population are provided in Table 1. 
Similarly, both groups were comparable in terms of 
angiographic and procedural characteristics. The 
only discrepancy between both study arms was 
less common baseline TIMI 3 flow in the prasugrel 
group (13 [28.3%] vs. 13 [52.0%]; p < 0.05).
None of the study participants developed new 
onset myocardial infarction or was diagnosed with 
definite stent thrombosis at 30-day follow-up. 
Symptoms of new onset chronic heart failure occur-
red in 14 (30.4%) patients treated with prasugrel 
and 8 (32.0%) participants receiving clopidogrel 
(p = NS). One (2.2%) patient from the prasugrel 
group reported an increased tendency for bruising. 
This patient continued therapy with prasugrel 
throughout the study period. No other bleeding 
events occurred in our study participants.
Platelet reactivity
The median time between administration of 
the 600 mg loading dose of clopidogrel and baseline 
blood sampling did not differ between the prasugrel 
and clopidogrel groups (21.0 [14.0–23.5] vs. 20.7 
[13.5–23.0] h; p = NS).
Platelet counts evaluated simultaneously 
with the baseline VASP and MEA measurements 
were comparable in the overall groups of patients 
assigned to the prasugrel and clopidogrel regimen 
(222 [193–258] vs. 243 [198–298] × 103 × mL–1; 
p = NS), as well as in the subgroups treated with-
out GP IIb/IIIa inhibitors (223 [200–255] vs. 232 
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[196–281] × 103 × mL–1; p = NS). Additionally, we 
found no significant correlation between both, the 
baseline PRI and ADP-induced platelet aggregation 
values, and the platelet count.
The baseline PRI was 60.1 [39.9–71.2]%; 46 
(64.8%) and 37 (52.1%) patients after pre-treat-
ment with a 600 mg loading dose of clopidogrel 
presented with PRI values above the thresholds 
of 50% and 60% indicating HTPR. Personalized 
antiplatelet treatment utilized in our study enabled 
adequate platelet inhibition both at 24 h and at 
30 days in the vast majority of our study participants 
(Figs. 2–5). The prasugrel regimen successfully 
overcame HTPR on clopidogrel in the acute phase 
of ACS and maintained its antiplatelet potency in 
30-day follow-up while continuation of clopidogrel 
therapy in patients with an initially appropriate 
response to a 600 mg loading dose of clopidogrel 
led to sufficient platelet inhibition in a predomi-
nant proportion of patients. In details, the median 
PRI value after loading with 30 mg of prasugrel 
sharply declined by 83% at 24 h and slightly, but 
significantly, rose between 24 h and 30 days (Fig. 2). 
However, the median PRI value at 30 days in the 
prasugrel group was merely equal to 40% of its 
baseline value. In contrast, median PRI values 
in the clopidogrel group were similar at baseline 
and at 24 h and then modestly rose at 30 days. As 
shown in Figure 4, treatment with prasugrel was 
associated in our study with a significantly lower 
Table 1. Baseline characteristics of the study population.
Variable Prasugrel group  
(n = 46)
Clopidogrel group  
(n = 25)
P
Age [years] 58.0 (54.0–65.0) 58.0 (56.0–64.0) NS
Gender (male/female) 10 (21.7%)/36 (78.3%) 10 (40.0%)/15 (60.0%) NS
Clinical presentation:
STEMI 34 (73.9%) 16 (64.0%) NS
NSTEMI 8 (17.4%) 7 (28.0%)
Unstable angina 4 (8.7%) 2 (8.0%)
Anterior location of STEMI 15 (44.1%) 9 (56.2%) NS
LVEF at discharge [%] 45.0 (40.0–50.0) 45.0 (40.0–50.0) NS
Prior myocardial infarction 11 (23.9%) 4 (16.0%) NS
Prior PCI 8 (17.4%) 4 (16.0%) NS
Prior CABG 2 (4.3%) 2 (8.0%) NS
Risk factors of coronary artery disease:
Body mass index [kg/m2] 27.2 (24.0–30.4) 27.4 (25.3–29.9) NS
Diabetes mellitus 12 (26.1%) 4 (16.0%) NS
Arterial hypertension 31 (67.4%) 12 (48.0%) NS
Current smokers 25 (54.4%) 15 (60.0%) NS
History of smoking 5 (10.9%) 3 (12.0%) NS
Positive family history 8 (17.4%) 8 (32.0%) NS
GFR [mL/min/1.73 m2] 93.9 ± 22.5 90.6 ± 17.6 NS
Total cholesterol (mg/dL) 217.8 ± 46.2 221.7 ± 45.4 NS
LDL cholesterol [mg/dL] 150.6 ± 42.0 148.1 ± 38.8 NS
HDL cholesterol [mg/dL] 43.5 (37.0–48.5) 47.0 (37.0–61.0) NS
Triglycerides [mg/dL] 118.5 (77.0–160.5) 99.0 (75.0–145.0) NS
Pharmacotherapy during hospitalization:
Statin use 46 (100.0%) 25 (100.0%) NS
Beta-blocker use 46 (100.0%) 25 (100.0%) NS
ACEI use 46 (100.0%) 24 (96.0%) NS
Proton pump inhibitors use 8 (17.4%) 4 (16.0%) NS
Calcium-channel blocker use 4 (8.7%) 0 (0.0%) NS
Glycoprotein IIb/IIIa inhibitor administration 16 (34.8%) 5 (20.0%) NS
ACEI — angiotensin-converting-enzyme inhibitor; GFR — glomerular filtration rate calculated according to the MDRD equation; CABG — coro-
nary artery bypass grafting; LVEF — left ventricular ejection fraction; NSTEMI — non-ST-segment elevation myocardial infarction; PCI — per-
cutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction
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median PRI value at 24 h than therapy with clopi-
dogrel. At baseline the numbers of patients with 
HTPR defined as the PRI value above the cut-offs 
of 50% and of 60% in the prasugrel and clopidogrel 
groups were: 46 (100%) vs. 0 (0%) for the cut-off 
of 50% and 36 (78.3%) vs. 0 (0%) for the cut-off of 
60%, at 24 h: 2 (4.3%) vs. 2 (8.0%) for the cut-off 
of 50% and 1 (2.2%) vs. 1 (4.0%) for the cut-off of 
60%, and at 30 days: 8 (17.4%) vs. 6 (24.0%) for 
the cut-off of 50% and 2 (4.3%) vs. 1 (4.0%) for the 
cut-off of 60%. Intra- and inter-group comparisons 
revealed a significant decrease in the proportion of 
patients treated with prasugrel and diagnosed with 
HTPR at 24 h when compared to their baseline sta-
tus (a p-value for both cut-offs < 0.0001). All other 
intra-group comparisons regarding the proportions 
Figure 2. Platelet reactivity index according to the antiplatelet regimen. Data are presented as medians and interquar-
tile ranges; p-values refer to differences within the same group between 2 consecutive sampling points.
Figure 3. Adenosine diphosphate (ADP)-induced platelet aggregation according to the antiplatelet regimen. Data are 
presented as medians and interquartile ranges; p-values refer to differences within the same group between 2 con-
secutive sampling points; *indicates measurements performed exclusively in patients not treated with glycoprotein 
IIb/IIIa inhibitors (20 and 30 patients in the clopidogrel and prasugrel groups, respectively); #indicates measurements 
performed in all study participants (25 and 46 patients in the clopidogrel and prasugrel groups, respectively).
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Figure 5. Individual patient values of adenosine diphosphate (ADP)-induced platelet aggregation at various sampling 
points according to the antiplatelet regimen. Boxes and whiskers represent medians, interquartile ranges and non-
-outlier ranges. A, B and C refer to measurements performed at baseline, at 24 h and at 1 month, respectively; high 
on-treatment platelet reactivity (HTPR) cut-off in the figure indicates the threshold of 46.8 U.
Figure 4. Individual patient values of platelet reactivity index at various sampling points according to the antiplatelet 
regimen. Boxes and whiskers represent medians, interquartile ranges and non-outlier ranges; A, B and C refer to me-
asurements performed at baseline, at 24 h and at 1 month, respectively; high on-treatment platelet reactivity (HTPR) 
cut-off in the figure indicates the threshold of 50%; PRI — platelet reactivity index.
of patients with HTPR at 2 consecutive sampling 
points as well as inter-group comparisons of the 
proportions of patients with HTPR at 24 h and at 
30 days indicated the lack of significant differences.
Baseline ADP-induced platelet aggregation as-
sessed exclusively in patients not treated with GP 
IIb/IIIa inhibitors (n = 50) was 17.5 [10.0–31.0] U. 
Three (6.0%) of these patients after pre-treatment 
with a 600 mg loading dose of clopidogrel presen-
ted with ADP-induced platelet aggregation values 
above both thresholds of 46.8 U and 54 U, thus 
indicating HTPR. In general, the pattern of platelet 
inhibition evaluated with MEA followed  tendencies 
observed with the VASP assay (Fig. 3), both in the 
prasugrel and clopidogrel groups. The median value 
of ADP-induced platelet aggregation after loading 
with 30 mg of prasugrel decreased by 47% at 24 h 
and remained stable at 30 days. On the other hand, 
the measurements of ADP-induced platelet aggre-
gation at all 3 sampling points were comparable in 
the clopidogrel group. As shown in Figure 5, tre-
atment with prasugrel was associated in our study 
with a significantly lower median value of ADP-in-
duced platelet aggregation at 30 days than therapy 
with clopidogrel. The baseline numbers of patients 
with HTPR defined as the ADP-induced platelet 
aggregation value above the cut-offs of 46.8 U 
and of 54.0 U in the prasugrel and clopidogrel 
groups were: 3 (10.0%) vs. 0 (0%) for the cut-off 
of 46.8 U and 3 (10.0%) vs. 0 (0%) for the cut-off of 
54.0 U, at 24 h: 0 (0%) vs. 1 (5.0%) for the cut-off 
of 46.8 U and 0 (0%) vs. 1 (5.0%) for the cut-off of 
54.0 U and at 1 month: 0 (0%) vs. 1 (5.0%) for the 
cut-off of 46.8 U and 0 (0%) vs. 1 (5.0%) for the 
cut-off of 54.0 U. Intra-group comparisons regar-
ding the proportions of patients treated either with 
prasugrel or clopidogrel and presenting with HTPR 
defined according to any of the applied definitions 
at 2 consecutive sampling points as well as inter-
-group comparisons of the proportions of patients 
with HTPR at any of the sampling points showed 
no significant differences.
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Discussion
The main finding of our study is that prasugrel 
overcomes on-clopidogrel HTPR in the acute phase 
of interventionally treated ACS and maintains its 
antiplatelet potency in 30-day follow-up. Platelet 
inhibition on prasugrel therapy in our study parti-
cipants with HTPR on clopidogrel was at least as 
effective as continuation of clopidogrel treatment 
in patients with an adequate response to a 600 mg 
loading dose of clopidogrel. Additionally, our results 
indicate that the 600 mg loading dose of clopidogrel 
fails to efficiently suppress platelet function in the 
acute phase of ACS according to the VASP assay in 
at least one half of patients undergoing PCI.
According to our best knowledge, this is the first 
study based on the VASP test in conjunction with 
another platelet function assay, reporting on the abi-
lity of prasugrel to overcome on-clopidogrel HTPR 
in ACS patients. In contrast to most of other trials 
[21–23], we also investigated the antiplatelet effects 
of both prasugrel loading and maintenance doses in 
ACS patients exhibiting HTPR on clopidogrel. Due 
to the unique property of the VASP assay to reflect 
selectively the inhibition of the P2Y12 receptor by 
antiplatelet agents, the VASP assay in contrast to 
other methods of platelet function monitoring may 
be applied in ACS patients treated with GP IIb/IIIa 
inhibitors. Previous studies on the efficacy of prasu-
grel in subjects with HTPR on clopidogrel therapy 
excluded persons receiving GP IIb/IIIa inhibitors 
and thus investigated highly selected populations 
[22, 24]. GP IIb/IIIa inhibitors are administered in 
individuals with unfavorable clinical characteristics 
including diabetic patients and those with extensive 
ST elevation myocardial infarction (STEMI), as well 
as in subjects with a high burden of intracoronary 
thrombus. These subsets of patients may potentially 
benefit most from intensified platelet inhibition. Si-
milarly, in our study, patients on adjunctive therapy 
with GP IIb/IIIa inhibitors when compared with 
those receiving exclusively aspirin and clopidogrel 
were numerically more likely to present with HTPR 
at baseline according to the VASP assay. Not only 
does the VASP assay facilitate the risk stratification 
process in ACS patients undergoing PCI [10–14], but 
according to a recent study, it also provides the best 
reflection of the in vivo plasma level of the active 
metabolite of clopidogrel when compared with light 
transmission aggregometry, Verify-Now® system, 
whole blood aggregometry, and the IMPACT-R 
ADP test [25]. Numerous pharmacodynamic stu-
dies including unselected patients in terms of their 
baseline platelet reactivity demonstrated that pra-
sugrel much stronger than clopidogrel, even with 
high doses of the latter (i.e. a loading dose of 600 
mg and a maintenance dose of 150 mg), inhibits 
ADP-induced platelet aggregation [20, 26–28]. 
This intensified platelet inhibition by prasugrel is 
believed to account for the reduction of ischemic 
events when compared with clopidogrel therapy 
in ACS patients undergoing PCI which was shown 
in the TRITON-TIMI 38 trial [4]. However, recent 
studies indicated that the phenomenon of HTPR 
also refers to subjects treated with prasugrel [20, 
21]. The prevalence of HTPR defined as the PRI 
value ≥ 50% measured 6–12 h after the administra-
tion of a 60 mg loading dose of prasugrel among 
301 ACS patients successfully treated with PCI in 
a multicenter French study was 25.2% [19]. This 
rate corresponds with the prevalence of HTPR 
on prasugrel at 30 days in the TRITON-TIMI 38 
platelet substudy (24% among 51 patients) [20], 
based on the same definition as applied by Bonello 
et al. [19].
In the first ever study demonstrating the 
efficacy of prasugrel in a broad range of post-PCI 
patients with HTPR on clopidogrel, Alexopoulos 
et al. [21] showed that prasugrel administered at 
a single dose of 10 mg per day more effectively 
inhibited platelet aggregation than clopidogrel at 
a high dose of 150 mg per day in 64 study partici-
pants. However, due to the specific study design 
(assessment of platelet reactivity at baseline, at 
30 days and at 60 days) conclusions regarding the 
antiplatelet effect of the compared regimens must 
be restricted to the chronic therapy and cannot be 
applied to the acute setting when most of cases of 
stent thrombosis occur. The same research group 
demonstrated in another randomized study inclu-
ding 60 STEMI patients with HTPR diagnosed with 
the use of the Verify-Now® system 2 h after loading 
with 600 mg of clopidogrel that prasugrel (60 mg 
loading dose/10 mg maintenance dose) provides 
faster and stronger platelet inhibition than a 150 mg 
maintenance dose of clopidogrel. The authors 
excluded from the study patients treated with 
GP IIb/IIIa inhibitors and applied only 1 method of 
platelet function monitoring. Sardella et al. [23] de-
monstrated in the randomized, crossover RESET 
GENE trial, including 32 patients with HTPR on 
standard clopidogrel regimen who underwent elec-
tive coronary stenting, that treatment with a 10 mg 
maintenance dose of prasugrel was associated with 
a significantly lower platelet reactivity than a 150 mg 
maintenance dose of clopidogrel (32.6 ± 10.5 
vs. 47.9 ± 20.9 U according to MEA, p = 0.028). 
No patient treated with prasugrel exhibited HTPR 
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defined as ADP-induced platelet aggregation with 
MEA > 45 U, whereas 9 (28.1%) receiving high-
-dose clopidogrel still had HTPR (p = 0.001).
Our results, when combined with the findings 
of other trials [21–24], provide a solid rationale for 
the conduction of a carefully designed randomized 
clinical trial aimed at testing potential clinical be-
nefits of personalized prasugrel-based antiplatelet 
therapy. In our opinion, such a trial including ACS 
patients undergoing coronary stenting should 
compare a non-selective strategy (treatment of all 
patients with prasugrel) with a selective approach 
(switching to prasugrel therapy only in patients 
with HTPR on clopidogrel). We believe that per-
sonalized antiplatelet therapy in ACS patients may 
potentially lead to a reduction of bleeding compli-
cations and thus possibly translate into mortality 
benefits as well as save financial resources and in 
consequence increase the availability of new pla-
telet P2Y12 inhibitors in low- and middle-income 
countries.
Limitations of the study
Several limitations to our study should be 
acknowledged. First, our study was performed in 
a non-randomized fashion. However, we believe 
that its design allows to prove our study hypothesis 
convincingly on the ability of prasugrel to overcome 
HTPR on clopidogrel in ACS patients and to clearly 
demonstrate that inhibition of platelet function with 
prasugrel in the setting of HTPR may be at least 
as effective as the antiplatelet effect of clopidogrel 
in non-HTPR patients. Furthermore, conduction of 
a reliable randomized study in the HTPR setting 
may create substantial difficulties. For example, in 
the TRIGGER-PCI trial, approximately one third 
of patients declined randomization when infor-
med that HTPR had been detected [29]. Second, 
since we only analyzed surrogate end points, the 
hypothesis that prasugrel improves prognosis in 
interventionally treated ACS patients with HTPR 
should be verified in adequately powered clinical 
trials. Third, the limited sample sizes of our study 
preclude comprehensive sub-group analyses. Fo-
urth, we did not analyze genetic polymorphisms 
involved in biotransformation of clopidogrel and 
prasugrel, nor did we assess active metabolites of 
thienopyridine derivatives [30]. Fifth, although the 
platelet VASP assay remains a very well validated 
method of platelet function monitoring, it requires 
an access to flow cytometry and a skilled technician 
to be performed.
Conclusions
Our study indicates that prasugrel overco-
mes HTPR on clopidogrel in the acute phase of 
interventionally treated ACS and maintains its 
antiplatelet potency in 30-day follow-up. Potential 
clinical benefits of personalized antiplatelet therapy 
based on prasugrel warrant further investigation 
in clinical trials in the ACS setting.
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